2023-09-12
This GENcast is part 1 of a 3-part series on Cas-CLOVER, “the proven alternative to CRISPR-Cas9,” sponsored by Demeetra AgBio—exclusive Cas-CLOVER licensing partner for bioprocessing, synthetic biotechnology, and agriculture. Here I sat down with Dr. Eric Ostertag, MD, PhD, Executive Chairman at Poseida Therapeutics, and Harvard/MIT professor Dr. George Church, PhD, who leads synthetic biology at the Wyss Institute. A wealth of gene editing experience, stories, and applications are shared in ...
